ALP, a biochemical marker of cholestasis, was reduced in Mdr2-/- mice by cilofexor therapy (Fig. 1A), while serum levels of liver transaminases ALT and AST, as well as BAs, remained unchanged (Fig. S2). This evidence concerns the gene GPT and cholestasis.